Upadacitinib
This oral JAK1-selective inhibitor is used to treat moderate to severe rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, and Crohn's disease in adults who have not responded adequately to other treatments. It works by blocking JAK1 enzymes that transmit inflammatory signals, reducing joint inflammation and skin symptoms. Due to risks of serious infections, blood clots, and cardiovascular events, it requires careful patient selection and monitoring.
Peso molecular
380,3700 g/mol
LogP
2,70
TPSA
78,30 Ų
Regla de cinco de Lipinski
Cumple
Áreas terapéuticas
Clases de fármacos
Mecanismo de acción
Selective JAK1 inhibitor reducing signaling from cytokines implicated in autoimmune diseases.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Selective JAK1 inhibitor reducing signaling from cytokines implicated in autoimmune diseases.
Estructura 2D
Cite this structure
Embed this structure
SMILES
CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
InChI
InChI=1S/C17H19F3N6O/c1-2-10-7-25(16(27)24-9-17(18,19)20)8-11(10)13-5-22-14-6-23-15-12(26(13)14)3-4-21-15/h3-6,10-11,21H,2,7-9H2,1H3,(H,24,27)/t10-,11+/m1/s1
Molecular Formula
C17H19F3N6O
HBD / HBA
2 / 6
Enlaces Rotables
3
Átomos Pesados
27
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
This oral JAK1-selective inhibitor is used to treat moderate to severe rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, and Crohn's disease in adults who have not responded adequately to other treatments. It works by blocking JAK1 enzymes that transmit inflammatory signals, reducing joint inflammation and skin symptoms. Due to risks of serious infections, blood clots, and cardiovascular events, it requires careful patient selection and monitoring.
Selective JAK1 inhibitor reducing signaling from cytokines implicated in autoimmune diseases.
Key pharmacokinetic parameters for Upadacitinib: Half-life: 9-14 hours.
Yes, Upadacitinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
Related Drugs
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3622821. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 58557659. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="upadacitinib"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/upadacitinib/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/upadacitinib/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/upadacitinib/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="upadacitinib"></drugfyi-drug>